NZ598518A - Concentrated polypeptide formulations with reduced viscosity - Google Patents

Concentrated polypeptide formulations with reduced viscosity

Info

Publication number
NZ598518A
NZ598518A NZ598518A NZ59851810A NZ598518A NZ 598518 A NZ598518 A NZ 598518A NZ 598518 A NZ598518 A NZ 598518A NZ 59851810 A NZ59851810 A NZ 59851810A NZ 598518 A NZ598518 A NZ 598518A
Authority
NZ
New Zealand
Prior art keywords
reduced viscosity
polypeptide formulations
concentrated polypeptide
formulation
dma
Prior art date
Application number
NZ598518A
Other languages
English (en)
Inventor
Tim Kamerzell
John Yuchang Wang
Sherry Martin-Moe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ598518A publication Critical patent/NZ598518A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ598518A 2009-08-04 2010-08-03 Concentrated polypeptide formulations with reduced viscosity NZ598518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23114009P 2009-08-04 2009-08-04
PCT/US2010/044258 WO2011017330A1 (en) 2009-08-04 2010-08-03 Concentrated polypeptide formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
NZ598518A true NZ598518A (en) 2014-12-24

Family

ID=43544629

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598518A NZ598518A (en) 2009-08-04 2010-08-03 Concentrated polypeptide formulations with reduced viscosity

Country Status (15)

Country Link
US (1) US20130236448A1 (https=)
EP (1) EP2461677A4 (https=)
JP (1) JP2013501058A (https=)
KR (1) KR20120047995A (https=)
CN (1) CN102573459A (https=)
AU (1) AU2010279569A1 (https=)
BR (1) BR112012002596A2 (https=)
CA (1) CA2769221A1 (https=)
IL (1) IL217887A0 (https=)
MX (1) MX2012001560A (https=)
NZ (1) NZ598518A (https=)
RU (1) RU2012108108A (https=)
SG (1) SG178226A1 (https=)
WO (1) WO2011017330A1 (https=)
ZA (1) ZA201200760B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP6125436B2 (ja) 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN111402950B (zh) * 2013-11-29 2024-03-19 豪夫迈·罗氏有限公司 抗体选择装置和方法
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013202A1 (es) * 1997-07-10 2000-12-13 Biotech Australia Pty Ltd Vacunas no acuosas
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EA200601714A1 (ru) * 2004-06-14 2007-06-29 Ю Эс Ви ЛИМИТЕД Способ получения пептидов
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos

Also Published As

Publication number Publication date
WO2011017330A1 (en) 2011-02-10
CA2769221A1 (en) 2011-02-10
SG178226A1 (en) 2012-03-29
JP2013501058A (ja) 2013-01-10
BR112012002596A2 (pt) 2015-09-15
MX2012001560A (es) 2012-06-01
CN102573459A (zh) 2012-07-11
AU2010279569A1 (en) 2012-03-01
WO2011017330A8 (en) 2011-04-21
ZA201200760B (en) 2013-05-29
EP2461677A4 (en) 2014-01-08
US20130236448A1 (en) 2013-09-12
KR20120047995A (ko) 2012-05-14
IL217887A0 (en) 2012-03-29
EP2461677A1 (en) 2012-06-13
RU2012108108A (ru) 2013-09-10

Similar Documents

Publication Publication Date Title
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
PH12019500517A1 (en) Long-acting formulations of insulins
AU2013334740A8 (en) Stable, low viscosity antibody formulation
WO2011104381A3 (en) Stable antibody containing compositions
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
PH12014502778B1 (en) Antibody formulation
NZ600096A (en) Formulations of antibody
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
MX342947B (es) Tratamiento de diabetes tipo 2.
UA100394C2 (en) Lipoic acid pellet composition
PH12012502139A1 (en) Orally disintegrating tablet containing acarbose
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
NZ600960A (en) Liquid compositions comprising vitamin d and uses thereof
GR20100100508A (el) Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου
NZ702107A (en) Avermectin pour-on formulation with reduced withdrawal time
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
UA49793U (ru) Применение 1'-гидрокси-пропан-3'-иминоцимарина как средства с кардиотоническим, диуретическим и противовоспалительным действием
UA50790U (en) thermoelectric material
PY1119799A (es) Formulaciones de insulina de acción prolongada

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENENTECH, INC., US

Free format text: OLD OWNER(S): GENENTECH, INC.; TIM KAMERZELL; SHERRY MARTIN-MOE; JOHN YUCHANG WANG

PSEA Patent sealed
LAPS Patent lapsed